UroGen raises $58.2M in bumped-up IPO

Oncology company UroGen Pharma Ltd. (NASDAQ:URGN) raised $58.2 million through the sale of 4.5 million shares at $13 in an IPO underwritten by Jefferies, Cowen, Raymond James and Oppenheimer. The price values the company at $155.6 million. The company announced the news after market hours Wednesday, and expects trading to begin Thursday.

Last month, the company hoped to sell 3.5 million shares at $12-$14. At the $13 midpoint, a sale of that many shares would have raised $45 million and valued the company at $142.5 million...